Sai Parenterals is set to acquire a majority stake in Bion Therapeutics through an all-cash deal, with completion expected before the end of the month, according to reports. The transaction will expand Sai Parenterals’ footprint in India’s prescription market.

The Hindu adds that the acquisition will bring 16 established brands and around 250 field staff, strengthening Sai Parenterals’ commercial reach in India. Business Line reports that, after the deal closes, Bion will become a step-down subsidiary of SAI Parenterals. Across outlets, the reports agree on the deal’s core structure—majority stake and all-cash consideration—even though they emphasize different supporting details about operational scale and corporate structure.